

# Comparison of fentanyl and remifentanyl for coronary artery surgery with low ejection fraction

Nukhet Baddal<sup>1</sup>, Cenk Conkbayir<sup>2</sup>, Ozcan Erdemli<sup>1</sup>, Umit Karadeniz<sup>1</sup>, Busra Tezcan<sup>1</sup>, Didem Melis Oztas<sup>3</sup>, Metin Onur Beyaz<sup>4</sup>, Murat Ugurlucan<sup>4</sup>, Yahya Yildiz<sup>5</sup>, Soner Yavas<sup>1</sup>

<sup>1</sup>Department of Anaesthesiology, Yuksek Ihtisas Hospital, Ankara, Turkey

<sup>2</sup>Department of Cardiology, Near East University, Nicosia (north), Cyprus

<sup>3</sup>Department of Cardiovascular Surgery, Bagcilar Education and Research Hospital, Istanbul, Turkey

<sup>4</sup>Department of Cardiovascular Surgery, Medipol University Hospital, Istanbul, Turkey

<sup>5</sup>Department of Anaesthesia, Medipol University Hospital, Istanbul, Turkey

**Submitted:** 5 November 2019

**Accepted:** 2 January 2020

Arch Med Sci Atheroscler Dis 2020; 5: e20–e26  
DOI: <https://doi.org/10.5114/amsad.2020.93528>  
Copyright © 2020 Termedia & Banach

**Corresponding author:**

Assoc. Prof. Cenk Conkbayir  
MD  
Department of Cardiology  
Near East University  
Yakın Doğu Bulvarı  
Nicosia, Cyprus  
E-mail: [cenkconk@hotmail.com](mailto:cenkconk@hotmail.com)

## Abstract

**Introduction:** In this study, we evaluated patient response and haemodynamic parameters in patients with low ejection fraction undergoing coronary bypass surgery with either fentanyl or remifentanyl in conjunction with etomidate.

**Material and methods:** We evaluated 30 cases of coronary artery surgery, which were divided into two treatment groups ( $n = 15$  each). In group F (fentanyl group), the following regimen was employed for anaesthesia induction: 1 mg/kg lidocaine, 0.3 mg/kg etomidate, and, following a 1 µg/kg 60 s bolus dose of fentanyl, a 0.1 µg/kg/min fentanyl infusion was initiated, after which 0.6 mg/kg rocuronium was administered. In group R (remifentanyl group), the following regimen was employed for anaesthesia induction: 1 mg/kg lidocaine, 0.3 mg/kg etomidate and, following a 1 µg/kg 60 s bolus dose of remifentanyl, a 0.1 µg/kg/min remifentanyl infusion was initiated, after which 0.6 mg/kg rocuronium was administered. Systolic artery pressure, diastolic artery pressure, mean arterial pressure, heart rate, SPO<sub>2</sub> (saturation), cardiac output, stroke volume variance, central venous pressure, and systemic vascular resistance values were recorded for all study patients at five minutes before anaesthetic induction (T1), immediately following induction (T2), and immediately following intubation (T3).

**Results:** The demographic values obtained for both groups were similar. We found that remifentanyl use was associated with decreased cardiac output and increased fluctuations in both heart rate and mean values of arterial pressure.

**Conclusions:** Although many studies have demonstrated remifentanyl to be as safe as fentanyl when titrated to an appropriate dose, our study suggests that fentanyl may be a more appropriate choice during the induction of anaesthesia in patients with a low ejection fraction.

**Key words:** low ejection fraction, coronary artery bypass surgery, anaesthesia.

## Introduction

In high-risk surgical cases in which haemodynamic parameters change rapidly, such as in cardiopulmonary bypass, a central objective

when inducing anaesthesia is to maintain cardiac output and oxygen delivery at appropriate levels.

In general anaesthesia, airway control is provided via laryngoscopy and endotracheal intubation [1]; the receptors in the airway are stimulated by both mechanical and chemical factors during these procedures. Stimulation of these tissues leads to catecholamine discharge via sympathetic adrenergic activation, resulting in increased arterial pressure, heart rate, and arrhythmia [1–6]. This response may aggravate existing pathologies in patients with coronary heart disease, cerebrovascular disease, and/or hypertension, which can lead to life-threatening complications [1, 2, 4, 7].

Current methods used to minimise the negative haemodynamic response caused by laryngoscopy and endotracheal intubation include blocking the activation of sensitive receptors and afferent nerves with local anaesthetic agents, inhibiting the central effects of painful stimuli with opioids, and suppressing efferent pathways and effector receptors with local anaesthetics,  $\beta$ -blockers, calcium channel blockers, and sympathetic ganglion blockers [8].

In this study we aimed to evaluate patient responses, the factors effecting those responses, and changes in haemodynamic parameters following anaesthetic induction and intubation, using either fentanyl or remifentanyl in conjunction with etomidate to induce anaesthesia, in coronary bypass surgery patients with an ejection fraction lower than 50%.

## Material and methods

Our study was conducted on patients undergoing coronary bypass surgery, for which we obtained local Ethics Committee approval. We evaluated 30 patients scheduled to undergo coronary artery surgery, each with an American Society of Anaesthesiologists (ASA) risk classification of II–III. Patients were provided with a volunteer consent form prior to inclusion in the study. Demographic data, ASA, and the presence of any additional diseases were all recorded in the study protocol. Patients with an ejection fraction of less than 20% or more than 50%, those requiring emergency surgery, and those with sensitivities to the drugs used in the study were excluded. All patients were premedicated with a 10 mg Diazem tablet one night before the operation and an intramuscular injection of 0.1 mg/kg morphine sulphate 30 min before the operation. While in the operating room, patients were subjected to ECG and monitored for levels of peripheral oxygen saturation (SpO<sub>2</sub>) and invasive arterial blood pressure (Drager Primus Anaesthesia Monitor, Lübeck, Germany).

For invasive arterial blood pressure monitoring, a 20 G (gauge) arterial cannula (BD, Faraday Road,

Swindon, UK) was used on the radial artery. For fluid infusion, a peripheral venous pathway was created with 18 G and 16 G branulas, through which 5–10 ml/kg/h isotonic sodium chloride was administered. A jugular venous catheter was inserted while the patient was conscious for the purpose of recording CVP. A Flotrac/Vigileo (Edward) monitor was used to measure each patient's cardiac output via SVV (Stroke Volume Variance) and systemic vascular resistance. BIS monitoring (Aspect Medical Systems Inc., Natick, MA, USA) was used to determine each patient's hypnotic status and depth of anaesthesia. BIS values  $\leq 50$  represented a sufficient depth of anaesthesia.

Patients were divided into two groups ( $n = 15$  each). Pre-oxygenation was provided by the application of 100% O<sub>2</sub>.

The anaesthesia induction protocol for group F (fentanyl group) included the following: 1 mg/kg lidocaine (Aritmal® 2%), 0.3 mg/kg etomidate (Etomidate®), 1  $\mu$ g/kg 60 s bolus dose fentanyl (Fentanyl®) followed by a 0.1  $\mu$ g/kg/min fentanyl infusion, 0.6 mg/kg rocuronium (Esmeron®). The anaesthesia induction protocol for group R (remifentanyl group) included the following: 1 mg/kg lidocaine (Aritmal® 2%), 0.3 mg/kg etomidate (Etomidate®), 1  $\mu$ g/kg 60 s bolus dose of remifentanyl (Ultiva®) followed by a 0.1  $\mu$ g/kg/min remifentanyl infusion, 0.6 mg/kg rocuronium (Esmeron®).

In both groups, etomidate was administered 5 min after opioid infusion via titration at a rate of 20 mg/min until the BIS value decreased to 50. Finally, rocuronium was administered.

During intubation, the degree of chin relaxation, ease of laryngoscopy, vocal cord status, and any presence of movement in the extremities were evaluated for each patient.

Systolic artery pressure (SAP), diastolic artery pressure (DAP), mean arterial pressure (MAP), heart rate (HR), SPO<sub>2</sub> (saturation), cardiac output (CO), stroke volume variance (SVV), central venous pressure (CVP), and systemic vascular resistance (SVR) values of all patients were recorded at the following time points: T1 – 5 min before the intubation, T2 – immediately following induction, T3 – immediately following intubation.

## Statistical analysis

SPSS 13.00 for Windows version package software (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. For analysis of continuous variables, conformity of normal distribution and homogeneity were tested with the Kolmogorov-Smirnov test. Categorical values were evaluated with the  $\chi^2$  test, and parametric values were evaluated with the independent samples *t*-test. Differences in consecutive measurements between the two groups were evaluated with repeat-

ed measures of ANOVA. Findings are presented as either mean values ± standard deviation (SD) or as percentages. *P*-values < 0.05 were accepted as statistically significant.

**Results**

Between the pre-induction (T1), post-induction (T2), and post-intubation (T3) periods, no significant differences were found between groups for the demographic values of SAP, DAP, MAP, HR, or SAT (*p* > 0.005) (Table I).

There were no significant differences found when comparing intergroup CVP values between T1 and T2, T1 and T3, or T2 and T3 for either the fentanyl or remifentanyl group (*p* > 0.05) (Table II). However, statistically significant differences were found when the same values were compared between the two groups in all pre-induction (T1), post-induction (T2), and post-intubation (T3) periods (*p* < 0.05) (Figure 1).

Statistically significant differences were found when intergroup MAP values were compared for both the fentanyl and remifentanyl groups between both T1 and T2, and T2 and T3 values (*p* < 0.05) (Table III). Additionally, while a significant difference was found between T1 and T3 in the fentanyl group (*p* < 0.05), no such difference was found in the remifentanyl group over the same time points (*p* > 0.05) (Figure 2).

In both groups, there were significant differences found for intergroup HRs between T1 and T2

(*p* < 0.05). However, no significant difference was observed for these groups between T1 and T3 (*p* > 0.05). While there was no significant difference observed in the fentanyl group between T2 and T3 (*p* > 0.05), there was a significant difference observed in the remifentanyl group (*p* < 0.05) (Table III, Figure 3).

No significant difference was observed for CO values within the fentanyl group between T1 and T2 (*p* > 0.05), although a significant difference was observed within the remifentanyl group over the same time points (*p* < 0.05). While there was a significant difference observed in the fentanyl group between T1 and T3 (*p* < 0.05), no such difference was observed in the remifentanyl group (*p* > 0.05). Additionally, there was no significant difference observed between T2 and T3 in the fentanyl group (*p* > 0.05); however, a significant difference was observed in the remifentanyl group (*p* < 0.05) (Table IV, Figure 4).

When CO values were compared between the two groups, there was a statistically significant difference found in the post-induction (T2) period (*p* < 0.05). However, there were no statistically significant differences found for the pre-induction (T1) and post-intubation (T3) periods (*p* > 0.005) (Figure 4).

When CVR values were compared between the two groups, there were no statistically significant differences found in either the pre-induction (T1), post-induction (T2), or post-intubation (T3) periods (*p* > 0.005) (Figure 5).

**Table I.** Comparison of systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, heart rate, and arterial oxygen saturation between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods


Variable	Group F (n = 15)	Group R (n = 15)	P-value	Total (n = 30)
SAP1	181.1 ±34.5	187.3 ±37.8	0.643	184.2 ±35.7
SAP2	131.3 ±31.9	133.6 ±24.0	0.823	132.5 ±27.7
SAP3	149.6 ±40.8	155.0 ±41.7	0.726	152.3 ±40.6
DAP1	85.0 ±9.3	82.3 ±11.2	0.476	83.7 ±10.2
DAP2	66.1 ±11.0	65.3 ±14.3	0.866	65.7 ±12.6
DAP3	80.7 ±17.7	82.5 ±29.6	0.841	81.6 ±24.0
MAP1	120.1 ±22.4	119.4 ±17.9	0.922	119.7 ±19.9
MAP2	92.0 ±20.0	84.6 ±21.0	0.333	88.3 ±20.5
MAP3	109.4 ±25.1	107.4 ±36.0	0.861	108.4 ±30.5
HR1	85.1 ±11.5	87.1 ±12.9	0.658	86.1 ±12.0
HR2	73.2 ±11.4	66.8 ±9.6	0.111	70.0 ±10.8
HR3	81.0 ±18.2	78.6 ±15.1	0.690	79.8 ±16.5
SAT1	94.8 ±3.0	92.8 ±4.5	0.168	93.8 ±3.9
SAT2	96.2 ±5.1	98.2 ±2.3	0.193	97.2 ±4.0
SAT3	99.0 ±0.0	98.9 ±0.2	0.326	98.9 ±0.1

SAP – systolic arterial pressure (mm Hg), DAP – diastolic arterial pressure (mm Hg), MAP – mean arterial pressure (mm Hg), HR – heart rate (BPM), SAT – arterial oxygen saturation (%), 1 – pre-induction, 2 – post-induction, 3 – post-intubation, F – fentanyl, R – remifentanyl.


**Table II.** Comparison of cardiac output, systemic vascular resistance and central venous pressure between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods

Parameter	Group F (n = 15)	Group R (n = 15)	P-value	Total (n = 30)
CO1	6.8 ±1.8	7.4 ±2.2	0.359	7.1 ±2.0
CO2	6.2 ±2.0	3.4 ±0.9	<b>0.0001</b>	4.8 ±2.1
CO3	5.6 ±1.8	6.1 ±3.2	0.611	5.9 ±2.5
SVR1	1236.1 ±408.9	1281.7 ±448.2	0.773	1258.9 ±422.2
SVR2	1274.0 ±255.0	1433.2 ±406.1	0.209	1353.6 ±342.8
SVR3	1251.2 ±249.7	1424.4 ±613.5	0.320	1337.8 ±468.6
CVP1	9.9 ±3.6	7.3 ±1.1	<b>0.014</b>	8.6 ±2.9
CVP2	10.5 ±3.6	7.6 ±1.1	<b>0.006</b>	9.0 ±3.0
CVP3	10.6 ±3.7	7.6 ±1.1	<b>0.007</b>	9.1 ±3.1

CO – cardiac output (l/dk), SVR – systemic vascular resistance (dyne\*s/cm<sup>2</sup>), CVP – central venous pressure (mm Hg), 1 – pre-induction, 2 – post-induction, 3 – post-intubation, F – fentanyl, R – remifentanyl.



**Figure 1.** Comparison of central venous pressure between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods



**Figure 2.** Comparison of mean arterial pressure between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods

<sup>£</sup>Intergroup MAP comparison; MAB1(T1) vs. MAB2(T2) p < 0.05.

<sup>α</sup>Intergroup MAP comparison; MAB2(T2) vs. MAB3(T3) p < 0.05.

<sup>η</sup>Intergroup MAP comparison; MAB1(T1) vs. MAB3(T3) p < 0.05.

Measurements of the degree of chin relaxation, ease of laryngoscopy, vocal cord status, the presence of cough, and the presence of movement in extremities during intubation were evaluated for each patient. In all patients, chin relaxation was

**Table III.** Comparison of intergroup parametric values

Comparison	Group F	Group R
SAP1 vs. SAP2	<b>0.0001</b>	<b>0.0001</b>
SAP1 vs. SAP3	<b>0.006</b>	<b>0.014</b>
SAP2 vs. SAP3	<b>0.043</b>	<b>0.028</b>
DAP1 vs. DAP2	<b>0.0001</b>	<b>0.0001</b>
DAP1 vs. DAP3	0.285	0.975
DAP2 vs. DAP3	<b>0.004</b>	<b>0.014</b>
MAP1 vs. MAP2	<b>0.001</b>	<b>0.0001</b>
MAP1 vs. MAP3	<b>0.039</b>	0.167
MAP2 vs. MAP3	<b>0.013</b>	<b>0.010</b>
HR1 vs. HR2	<b>0.0001</b>	<b>0.0001</b>
HR1 vs. HR3	0.318	0.059
HR2 vs. HR3	0.150	<b>0.004</b>


SAP – systolic arterial pressure (mm Hg), DAP – diastolic arterial pressure (mm Hg), MAP – mean arterial pressure (mm Hg), HR – heart rate (BPM), 1 – pre-induction, 2 – post-induction, 3 – post-intubation, F – fentanyl, R – remifentanyl.

complete, laryngoscopy was easy, and vocal cords were completely immobile. Neither cough nor limb movements were observed in any of the patients during surgery.


**Discussion**

The pharmaceutical agents used for the induction of anaesthesia commonly lead to decreases in blood pressure, while laryngoscopy and intubation increase haemodynamic parameters.

A central goal during cardiac surgery is the maintenance of adequate tissue perfusion in the patient. A widely used indicator to monitor this adequacy, particularly in patients who are not haemodynamically stable, is the measurement of



**Figure 3.** Comparison of heart rate between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods



**Figure 4.** Comparison of cardiac output between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods


cardiac output. In the past, measuring cardiac output involved insertion of a pulmonary artery catheter prior to surgery; however, cardiac output can now be measured using the more practical and less invasive FloTrac/Vigileo system. Breukers *et al.* [9] found that measuring the rate of change in cardiac output obtained over consecutive time periods is a more effective method for determining patient treatment protocols than relying on static cardiac output values. Furthermore, measurements of this rate of change should be similar whether they are obtained using the FloTrac/Vigileo system or by the thermo dilution method because a good correlation has been found between these two techniques. Additionally, increases in vascular tonus, as obtained from measuring cardiac output values using FloTrac/Vigileo equipment, are reflected by small increases in these values; thus, the measurement algorithm retains adequate sensitivity to detect dynamics for this haemodynamic parameter.

Cengiz *et al.* [10] previously examined patient responses to various remifentanyl doses following a 2.5 mg/kg intravenous bolus of propofol. Patients in this study were divided into three groups: group I was administered 0.5 µg/kg remifentanyl, group II was administered 1 µg/kg remifentanyl, and group III was administered 2 µg/kg remifentanyl. While

**Table IV.** Comparison of intergroup arterial oxygen saturation, cardiac output, systemic vascular resistance, and central venous pressure values

Comparison	Group F	Group R
SAT1 vs. SAT2	0.362	<b>0.0001</b>
SAT1 vs. SAT3	<b>0.0001</b>	<b>0.0001</b>
SAT2 vs. SAT3	0.058	0.240
CO1 vs. CO2	0.084	<b>0.0001</b>
CO1 vs. CO3	<b>0.028</b>	0.162
CO2 vs. CO3	0.278	<b>0.005</b>
SVR1 vs. SVR2	0.615	0.096
SVR1 vs. SVR3	0.837	0.348
SVR2 vs. SVR3	0.540	0.952
CVP1 vs. CVP2	0.228	0.262
CVP1 vs. CVP3	0.060	0.055
CVP2 vs. CVP3	0.499	0.670

SAT – arterial oxygen saturation, CO – cardiac output (l/dk), SVR – systemic vascular resistance (dyne\*s/cm<sup>2</sup>), CVP – central venous pressure (mm Hg), 1 – pre-induction, 2 – post-induction, 3 – post-intubation, F – fentanyl, R – remifentanyl.



**Figure 5.** Comparison of systemic vascular resistance (SVR) between fentanyl and remifentanyl groups during pre-induction, post-induction, and post-intubation periods

heart rate measurements following intubation were significantly higher than pre-induction values in groups I and II, in group III post-induction heart rates were found to be significantly less than those measured during pre-induction. Overall, as the remifentanyl dose was increased, a concomitant decrease in patient heart rates was observed. In the current study, when a 1 µg/kg dose of remifentanyl was administered, post-intubation heart rates were found to be significantly higher than post-induction heart rates, and no significant difference was found when comparing these values to pre-induction heart rates.

Güneş *et al.* [11] compared the effects of remifentanyl and fentanyl administration in conjunction with desflurane on intracranial inter-

vention patients with regard to intubation, skin incision, haemodynamic changes following implementation of the head holder, and eye opening and response time to verbal commands during extubation at the end of the surgery. While increased haemodynamic values were detected in the fentanyl group during intubation, skin incision, and head holder implementation, a more stable haemodynamic profile was observed in the remifentanyl group ( $p < 0.05$ ). In our study, in both the fentanyl and remifentanyl groups, SAP, DAP, MAP, and HR values decreased during induction and increased during intubation, but there were no significant differences detected between the two groups for these values ( $p > 0.05$ ). Fluctuations in MAP and HR values were more severe in the remifentanyl group; however, the significant decrease in cardiac output values measured for the remifentanyl group may be related to the low ejection fraction values of our selected patient group. In patients with normal ejection fractions, Kazmaier *et al.* [12] found that a high dose of remifentanyl significantly decreased heart rate, mean arterial pressure, myocardial blood flow, and systemic vascular resistance values.

Gezer *et al.* [13] compared patients' cardiac stability in response to the administration of either remifentanyl, alfentanil, or fentanyl during anaesthetic induction. Patients were divided into three groups: Group I intravenously received 1 µg/kg remifentanyl, group II intravenously received 15 µg/kg alfentanil, and group III intravenously received 2 µg/kg fentanyl. Following this, all three groups received 2 mg/kg propofol and 0.6 mg/kg rocuronium. Statistically significant decreases were observed in HR values in groups I and II when comparing time points taken immediately prior to laryngoscopy versus during pre-induction. When intergroup HR values were compared, the HR increases found in groups II and III at 1 min after intubation were found to be statistically significant. However, this study utilised a higher single dose of remifentanyl than we used cumulatively over the entirety of the surgical procedure. This may explain the lack of significant difference found between heart rate values in our study. Furthermore, administering etomidate during the induction of anaesthesia (as in our study) may lead to a more balanced induction than propofol in terms of haemodynamic stability. In particular, considering that our patients had poor ventricular function, the use of etomidate may be even more effective at preserving cardiac stability than direct comparison with previous studies might indicate.

Zhang and Sun [14] compared how the use of fentanyl, remifentanyl, or alfentanil in conjunction with etomidate during anaesthetic induction affected patients' haemodynamic parameters during elective abdominal surgery. A total of

90 ASA I-II patients were divided into three groups: group F patients received 1 µg/kg fentanyl as a 60-second bolus dose, group R patients received 1 µg/kg remifentanyl as a 60-second bolus dose, and group A patients received 0.1 µg/kg sufentanil as a 60-second bolus dose. Doses were continued at 0.1, 0.1, and 0.01 µg/kg/min, respectively, as continuous infusions. Blood pressure and heart rate values were recorded at five different time points. While endotracheal intubation led to significant increases in blood pressure and heart rate in groups F and S, there was no significant change observed in group R ( $p < 0.01$ ), although greater haemodynamic changes occurred in group F than in the other groups ( $p < 0.01$ ). In group R, there was an average heart rate decrease of more than 30% following induction ( $p < 0.01$ ). Thus, remifentanyl was observed to be the most effective choice for suppressing the development of cardiovascular response following endotracheal intubation. In our study, however, though the use of fentanyl and remifentanyl led to equivalent post-induction heart rate decreases amongst patients, any increases in heart rate that were measured following intubation were not found to be significant in the fentanyl group. However, these measurements were significant in the remifentanyl group, which suggests that remifentanyl may not be as successful at providing haemodynamic stability as the Zhang study suggests.

There is controversy in the literature as to whether fentanyl is effective for preventing the hypertension and tachycardia that develop during endotracheal intubation and laryngoscopy. For example, Splinter and Cervenko [15], Chung and Evans [16], and Chung *et al.* [17] all reported that fentanyl is effective at preventing HR and SAP increases when administered at a range of doses (all at 5 µg/kg or less) either immediately prior to or during intubation. However, Kautto [18] found that while 2 µg/kg of fentanyl significantly controlled patients' arterial pressure and heart rate measurements, a 6 µg/kg dose was unable to provide the same effect. In the current study, we administered fentanyl at a dose of 1 µg/kg, 5 min prior to intubation. Similar to what was found in previous studies, we concluded that at this dose fentanyl was able to prevent both hypertension and tachycardia from developing during endotracheal intubation and laryngoscopy.

Howie *et al.* [19] compared the effects of three different remifentanyl doses on coronary artery bypass patients with poor left ventricle function. For this study, 72 patients were divided into three groups: group 1 patients ( $n = 23$ ) received a 1 µg/kg/min remifentanyl infusion, group 2 patients ( $n = 24$ ) received a 2 µg/kg/min remifentanyl in-

fusion, and group 3 patients ( $n = 25$ ) received a 3  $\mu\text{g}/\text{kg}/\text{min}$  remifentanyl infusion. If a sufficient depth of anaesthesia was not obtained using these doses, then additional remifentanyl was given in either 1–2  $\mu\text{g}/\text{kg}$  bolus doses or infusion increases, and 0.5–1.0% isoflurane was administered. Remifentanyl alone (whether by infusion or bolus administration) prevented haemodynamic reflex responses in 44% of the patients in group 3, 37% in group 2, and 9% in group 1. Hypotension developed in 64–75% of patients. In coronary bypass surgery patients with poor left ventricle function who were premedicated with lorazepam, effective anaesthesia was obtained with a 2–4  $\mu\text{g}/\text{kg}/\text{min}$  remifentanyl infusion and the administration of occasional low concentration isoflurane. In our study, there were significant decreases in both mean arterial pressure and heart rate values following induction, and these values significantly increased after intubation following a 1  $\mu\text{g}/\text{kg}$  bolus or a 0.1  $\mu\text{g}/\text{kg}/\text{min}$  remifentanyl infusion. Neither of these dosing strategies prevents haemodynamic reflex responses.

In conclusion, in this study, we compared the effects on haemodynamics and intubation responses following the use of either fentanyl or remifentanyl during anaesthetic induction in patients with an ejection fraction of less than 50% while they underwent coronary bypass surgery. Decreased cardiac output levels and increased fluctuations in heart rate and mean arterial pressures were observed following the administration of remifentanyl. It is important to note that, although achieving an appropriate dose titration is an important consideration when using opioid agents for anaesthesia, the proper selection of hypnotic agent to use in conjunction with a given opioid is extremely important as well. Although many studies that have employed remifentanyl during the induction of anaesthesia have concluded that it is as safe as fentanyl when appropriately titrated to the patient, our study suggests that fentanyl may be a more appropriate choice during this period in patients presenting with a low ejection fraction.

### Conflict of interest

The authors declare no conflict of interest.

### References

1. Hamaya Y, Dohi S. Differences in cardiovascular response to airway stimulation at different sites and blockade of the responses by lidocaine. *Anesthesiology* 2000; 93: 95-103.
2. Collins VJ. Intravenous anesthesia: narcotic and neuroleptic agents. In: Principles of Anesthesiology. 3<sup>rd</sup> edn. Collins VJ (ed.). Lea & Febiger, Philadelphia 1993; 571-75.
3. Derbyshire DR, Chimelewski A, Fell D, Vater M, Achola K, Smith G. Plasma catecholamine responses to tracheal intubation. *Br J Anaesth* 1993; 55: 855-60.
4. Edwards ND, Alford AM, Dobson PMS, Peacock JE, Reilly CS. Myocardial ischaemia during tracheal intubation and extubation. *Br J Anaesth* 1994; 73: 537-9.
5. Kayhan Z. Pathophysiologic effects and complications of intubation. In: Clinical Anesthesia. 2<sup>nd</sup> edn. Logos Publications, Istanbul 1997; 239-40.
6. Kaplan JD, Schuster DP. Physiologic consequences of tracheal intubation. *Clin Chest Med* 1991; 12: 425-32.
7. Millar FA, Dally FG. Acute hypertension during induction of anesthesia. *Br J Anaesth* 1970; 42: 618-24.
8. Kayhan Z. Endotracheal intubation. In: Clinical Anesthesia. Expanded 3<sup>rd</sup> ed. Logos Publications, Istanbul 2004; 243-306.
9. Breukers RM, Sepehrkhoy S, Spiegelberg SR, Groeneveld AB. Cardiac output measured by a new arterial pressure waveform analysis method without calibration compared with thermodilution after cardiac surgery. *J Cardiothorac Vasc Anesth* 2007; 21: 632-5.
10. Cengiz M, Ganidađlı S, Ölmez G. Endotracheal intubation without muscular relaxants: comparison of three different remifentanyl doses following Propofol induction. *J Turk Anesthesiol Reanim Soc* 2004; 32: 356-61.
11. Güneş Y, Gündüz M, Ünlügenç H, Özcengiz D, Balcioglu O, Işık G. Comparison of desfluran-remifentanyl with desfluran-fentanyl anesthesia in intracranial interventions on hemodynamics and recovery. *J Turk Anesthesiol Reanim Soc* 2003; 31: 37.
12. Kazmaier S, Hanekop GG, Buhre W, Weyland A, Busch T. Myocardial consequences of remifentanyl in patients with coronary artery disease. *Br J Anaesth* 2000; 84: 578-83.
13. Gezer A, Arslan G, Berkel G, Sezen Ö, Gürsu T, Arkan Z. Comparison of remifentanyl, alfentanil and fentanyl for prevention of hemodynamic response develops for laryngoscopy and endotracheal intubation. *Med J Kartal Training Res Hospital* 2002; 1: 16.
14. Zhang GH, Sun L. Peri-intubation hemodynamic changes during low dose fentanyl, remifentanyl and sufentanil combined with etomidate for anesthetic induction. *Chin Med J (Engl)* 2009; 122: 2330-4.
15. Splinter W, Cervenka F. Haemodynamic responses to laryngoscopy and tracheal intubation in geriatric patients: effects of fentanyl, lidocaine and thiopentone. *Can J Anaesth* 1989; 36: 370-6.
16. Chung F, Evans D. Low-dose fentanyl: haemodynamic response during induction and intubation in geriatric patients. *Can Anaesth Soc J* 1985; 32: 622-8.
17. Chung KS, Sinatra RS, Halevey JD, Paige D, Silverman DG. A comparison of fentanyl, esmolol their combination for blunting the hemodynamic responses during rapid sequence induction. *Can J Anaesth* 1992; 39: 774-9.
18. Kautto UM. Attenuation of the circulatory response to laryngoscopy and intubation by fentanyl. *Acta Anaesthesiol Scand* 1982; 26: 217-21.
19. Howie MB, Michelsen LG, Hug CC Jr, et al. Comparison of three remifentanyl dose-finding regimens for coronary artery surgery. *J Cardiothorac Vasc Anesth* 2003; 17: 51-9.